Stock

Contineum Therapeutics, Inc. CTNM

$14.12-1.29%

All stocks Create account to unlock

Overview

CTNM market data

Price History

CTNM price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for CTNM. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

3 captured

8-K filing — Contineum Therapeutics, Inc. (CTNM) · Jul 13, 2026, 8:15 PM

Contineum Therapeutics Publishes 'Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders' In Journal of Medicinal Chemistry · Jun 30, 2026, 8:10 PM

Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16 · May 14, 2026, 4:45 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock